Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | BRD2 | P25440 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9056134 | 1.00 | ALOX5 (0.43) | ALOX5PIK3CDKMT2AGAARAB9A | |
| SCHEMBL28520481 | 0.94 | GAA (0.42) | ALOX5PIK3CDKMT2AGAARAB9A | |
| SCHEMBL9056711 | 0.94 | ALOX5 (0.46) | ALOX5PIK3CDKMT2AGAARAB9A | |
| SCHEMBL7801728 | 0.94 | ALOX5 (0.46) | ALOX5PIK3CDKMT2AGAARAB9A | |
| SCHEMBL9056157 | 0.94 | RAB9A (0.43) | ALOX5PIK3CDKMT2AGAARAB9A | |
| SCHEMBL7801906 | 0.89 | RAB9A (0.42) | ALOX5PIK3CDKMT2AGAARAB9A | |
| SCHEMBL7802935 | 0.88 | GAA (0.42) | ALOX5PIK3CDKMT2AGAARAB9A | |
| SCHEMBL9653498 | 0.88 | GAA (0.42) | ALOX5PIK3CDKMT2AGAARAB9A | |
| SCHEMBL9654604 | 0.86 | PIK3CD (0.47) | PIK3CDKMT2ARAB9AMEN1PKM | |
| SCHEMBL297738 | 0.84 | ALOX5 (0.53) | ALOX5PIK3CDKMT2AGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215888-A1 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2009-08-27 | — | — | US | claimed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | claimed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | claimed |
| WO-2007098591-A2 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2007-09-07 | — | — | WO | claimed |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-08-09 | — | — | US | claimed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | claimed |
| US-7137975-B2 | Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent | ACIONT, INC. (US) | 2006-11-21 | — | — | US | claimed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | claimed |
| EP-1140021-B1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2004-08-04 | — | — | EP | claimed |
| US-6620788-B1 | Enteral sorbefacients | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2003-09-16 | — | — | US | claimed |
| US-5371238-A | Reacting 1-/n-alkenyl/-azacycloalkan-2-one with alkyl mercaptan using free radical initiator, reducing, distilling to purify | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1994-12-06 | — | — | US | claimed |
| EP-0610502-A1 | EMULSION CONTAINING PARATHYROID HORMONE FOR PERNASAL ADMINISTRATION | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1994-08-17 | — | — | EP | claimed |
| US-5281580-A | Respiratory system disorders | TOYO JOZO COMPANY, LTD. (JP) | 1994-01-25 | — | — | US | claimed |
| EP-0471618-B1 | CALCITONIN-CONTAINING EMULSION FOR NASAL ADMINISTRATION | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1993-09-29 | — | — | EP | claimed |
| EP-0555483-A1 | PROCESS FOR PRODUCING AZACYCLOALKANE DERIVATIVE | Hisamitsu Pharmaceutical Co., Inc. (JP) | 1993-08-18 | — | — | EP | claimed |
| EP-0241050-B1 | AZACYCLOALKANE DERIVATIVES, ABSORPTION PROMOTERS CONTAINING THE DERIVATIVES AS THE EFFECTIVE INGREDIENT AND EXTERNAL PREPARATION CONTAINING THE ABSORPTION PROMOTERS | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1992-10-14 | — | — | EP | claimed |
| EP-0471618-A1 | Calcitonin-containing emulsion for nasal administration | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1992-02-19 | — | — | EP | claimed |
| US-4882359-A | USED WITH DRUGS | HISAMITSU PHARMACEUTICAL CO., LTD. (JP) | 1989-11-21 | — | — | US | claimed |
| WO-1987006226-A2 | AZACYCLOALKANE DERIVATIVES, ABSORPTION PROMOTERS CONTAINING THE DERIVATIVES AS THE EFFECTIVE INGREDIENT AND EXTERNAL PREPARATIONS CONTAINING THE ABSORPTION PROMOTERS | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1987-10-22 | — | — | WO | claimed |
| EP-0241050-A2 | Azacycloalkane derivatives, absorption promoters containing the derivatives as the effective ingredient and external preparation containing the absorption promoters | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1987-10-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | GPX4, LPO, MMP8 | ALOX5 68/4885PIK3CD 3109/4885KMT2A 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.